Pulmatrix, Inc.
PULMNasdaqHealthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | — | $7.8M | $7.3M | $6.1M | $5.2M | $12.6M |
| Operating income | −$5.2M | −$9.8M | −$14.7M | −$18.9M | −$20.2M | −$9.9M |
| Net income | −$5.2M | −$9.6M | −$14.1M | −$18.8M | −$20.2M | −$19.3M |
| Total assets | $4.1M | $9.9M | $34.0M | $41.0M | $58.8M | $38.1M |
| Total liabilities | $329,000 | $996,000 | $16.0M | $9.8M | $11.4M | $15.0M |
| Equity | $3.8M | $8.9M | $18.0M | $31.1M | $47.4M | $23.1M |
| EPS (diluted) | $-1.41 | $-2.62 | $-3.87 | $-5.46 | $-8.63 | — |
| Shares out. | 3.7M | 3.7M | 3.7M | 3.3M | 56.2M | 20.5M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- —
- Net margin
- —
- Return on equity
- −135.5%
- Return on assets
- −124.7%
- Return on capital (ROCE)
- −135.7%
- Liabilities / assets
- 7.9%
- Debt / equity
- 0.09×
- Book value / share
- $1.04
- Revenue growth (YoY)
- —
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- -228.32distress
- Accruals / assets
- 6.5%moderate
- Piotroski F-Score
- 3/7weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 1 severe● 1 warning● 1 good- Altman Z″ in the distress zone
- Negative operating cash flow
- Conservative leverage (liabilities < 50% of assets)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Rcm Eos Pipe Holdings, LlcActivist (13D)Apr 22, 2026
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 33,902 | 2.1 | -16.1% |
| Apr 30, 2026 | 40,413 | 1.0 | +106.2% |
| Apr 15, 2026 | 19,602 | 1.0 | +143.4% |
| Mar 31, 2026 | 8,053 | 1.0 | +221.5% |
| Mar 13, 2026 | 2,505 | 1.0 | -9.9% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Results of operationsMay 15, 2026
- Regulation FD disclosure · Other material eventApr 21, 2026
- Entered a material agreement · Unregistered equity sale · Modified shareholder rights · Change in control · Amended charter or bylaws · Regulation FD disclosureMar 27, 2026
- Terminated a material agreement · Regulation FD disclosureMar 2, 2026
- Results of operationsFeb 26, 2026
- Regulation FD disclosure · Other material eventDec 18, 2025
- Results of operationsOct 16, 2025
- Results of operationsAug 6, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.